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Abstract 
Introduction: Inadvertent removal of, or damage to, the parathyroid glands in the course of 
operations on the anterior neck compartment are responsible for over 80% of cases of chronic 
hypoparathyroidism (HypoPT). This study searched for factors related to the development of 
permanent HypoPT after total thyroidectomy and central neck lymphadenectomy in patients 
with thyroid carcinoma.  
Material and methods: In total, 89 of 103 screened patients met the study’s criteria and were 
put under prospective one-year observation. Demographic and surgical factors as well as the 
biochemical parameters of mineral homeostasis, controlled both preoperatively and 
postoperatively, were subject to statistical analysis. In line with contemporary guidelines, 
postoperative hypocalcaemia, rather than an abnormally low serum parathormone (PTH) 
concentration, was considered a diagnostic criterion of HypoPT.  
Results: On postoperative day one (POD1), serum concentration of PTH decreased below the 
normal range (< 12 pg/mL) in 29 patients and was undetectable in 19 patients (< 6 pg/mL). At 
one year postoperatively, 12 patients with undetectable POD1 PTH required treatment for 
hypocalcaemia and were diagnosed with permanent hypoPT. All the other patients regained 
normocalcaemia. Relative risk of permanent HypoPT associated with undetectable POD1 
PTH was 88.75. A significant difference in median POD1 serum calcium concentration 
between the patients with undetectable POD1 PTH and those with detectable POD1 PTH was 
found (p < 0.001). The difference between the POD1 serum calcium in patients with 
permanent or transient HypoPT in the subgroup with undetectable POD1 PTH did not reach 
the level of statistical significance (median, 1.82 mmol/L vs. 1.96 mmol/L). At one month 
postoperatively, in patients who later developed permanent HypoPT, serum calcium was 
lower than it was in all other patients (p = 0.167). At one year postoperatively, serum 
concentration of PTH was in the normal range in 10 of 12 patients with permanent HypoPT; 
however, it was significantly lower than it had been before the operation and distinctly lower 
than it was in patients who regained normocalcaemia. The number of parathyroid glands 
either dissected or autotransplanted did not affect the development of permanent HypoPT. 
Conclusions: Undetectable POD1 PTH is an important risk factor of permanent HypoPT. The 
main cause of permanent HypoPT was irreversible damage to the left in situ parathyroid 
glands. 
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Introduction 
Anatomical relations and common blood supply make parathyroid glands vulnerable to 
damage in the course of total thyroidectomy. Parathyroid hormone enhances calcium 
reabsorption in the kidney and activates vitamin 1.25(OH)2D3 synthesis, which increases 
intestinal absorption of calcium and phosphate, and directly stimulates the release of calcium 
and phosphate from bone [1]. The promotion of renal phosphate excretion provides protection 
from renal and other soft tissue calcifications as well as bone mineralisation disturbances, 
which result from hyperphosphataemia [2, 3]. The physiological, intermittent secretion of 
parathormone (PTH) has a stimulatory effect on bone formation and indirectly enhances bone 
resorption, which prevents bone ageing and brittleness [4]. While hypocalcaemia alone may 
be satisfactorily managed with the use of calcium supplements and active vitamin D 
metabolites, standard treatment of hypoparathyroidism (HypoPT) cannot fully replace the 
multidirectional activity of PTH. Therefore, chronic HypoPT has a negative impact on quality 
of life [3, 5, 6].  
Postsurgical hypofunction of the parathyroid glands is the most prevalent aetiology of 
HypoPT [2]. The time between transient and permanent HypoPT is usually 6–12 months 
postoperatively [2, 7, 8]. Some authors have diagnosed protracted HypoPT in patients who 
require treatment for hypocalcaemia at 4–6 weeks postoperatively [9, 10]. According to the 
European Society of Endocrinology’s (ESE) recent guidelines on the treatment of chronic 
HypoPT in adults, in the presence of hypocalcaemia a specific cut-off limit for serum PTH 
concentration cannot be defined because hypocalcaemia should normally induce a marked 
increase in PTH secretion [7]. However other causes of hypocalcaemia, such as hungry bone 
syndrome, secondary hyperparathyroidism, or chronic hypomagnesaemia should be 
considered.  
The issue of risk factors of permanent HypoPT is underrepresented in the current medical 
literature; this is primarily because health care in the perioperative period is divided between 
surgeons, endocrinologists, and family doctors, working separately. The risk of permanent 
HypoPT is increased with total vs. subtotal thyroidectomy, completion thyroidectomy, 
reoperations for bleeding, and central node dissection [11–13]. The aim of this prospective 
observational study was to determine factors that are related to the development of permanent 
HypoPT in patients who are diagnosed with papillary carcinoma of the thyroid and are 
undergoing total thyroidectomy with central lymph node dissection. An understanding of 
factors that herald permanent hypocalcaemia would provide surgeons with early information 
on postoperative outcomes and allow the personalisation of postoperative treatments.  
Material and methods 
In this study 103 patients who were scheduled for surgical treatment in our department 
between 2014 and 2016 and who were willing to attend regular medical appointments were 
screened for participation. All patients were diagnosed with papillary thyroid carcinoma based 
on a fine needle aspiration biopsy. Inclusion criteria included the following: normal 
biochemical results of calcium metabolism, normal serum albumin and total protein, normal 
thyroid, liver, and kidney function, and normal 24-hour urine calcium excretion.  
Cases of completion thyroidectomy and patients with diseases or who were taking 
medications that affect calcium homeostasis were excluded. Vitamin D deficiency was not an 
exclusion criterion unless it was accompanied by secondary hyperparathyroidism.  
The study received local ethical board approval, and each participant received and signed an 
informed consent form.   
Total extracapsular excision of the thyroid gland with lymphadenectomy of the central neck 
compartment was performed on each patient by the same team of surgeons. At least two 
parathyroids were visualised intraoperatively. In each case the thyroid was devascularised by 
selective closure of distal branches of the thyroid arteries to spare the vascular supply of the 
parathyroids.  
Biochemical monitoring of mineral homeostasis included the following: serum calcium 
(Calcium Arsenazo III, Beckman Coulter, Inc., normal range: 2.2–2.65 mmol/L) phosphate 
(Inorganic Phosphorous, Beckman Coulter, Inc., normal range: 0.81–1.45 mmol/L) , 
magnesium (Magnesium, Beckman Coulter, Inc., normal range: 0.77–1.06 mmol/L), PTH 
(Access Intact PTH Assay, Beckman Coulter, Inc., normal range: 12–88 pg/mL), and 25-
hydroxy vitamin D3 (Elecsys2010 Vitamin Total II, Cobas e, Roche Diagnostics GmbH, 
normal range: > 20 mg/mL). A decrease in serum albumin concentration by 1g/dL leads to a 
drop in the total serum calcium concentration by 0.2 mmol/L. In line with the inclusion 
criteria, the serum albumin was normal in all participants. In the early postoperative period, 
patients with biochemical hypocalcaemia — which was defined as a serum calcium 
concentration below 2 mmol/L — as well as symptomatic hypocalcaemia — which was 
understood as symptoms associated with serum calcium decrease — were given calcium 
carbonate, magnesium lactate, and alphacalcidol orally, as well as calcium gluconate 
intravenously, when needed.  
The abovementioned laboratory tests were performed one week prior to surgery, on 
admission, and daily, starting from postoperative day one (POD1) (serum calcium, 
magnesium, PTH) until discharge from the hospital. Thereafter, the tests were repeated after 
7–14 days and in 4–5-week intervals until both active vitamin D and calcium could be 
discontinued. All patients were followed-up by the same endocrinologist throughout the 
study. The final statistical analysis was based on the results that were obtained one year 
postoperatively. Patients with normal or elevated serum phosphate and normal magnesium 
concentrations, who required treatment for hypocalcaemia, were diagnosed with permanent 
HypoPT. 
The numbers of parathyroids that were transplanted into the sternocleidomastoid muscle as 
well as of those found in pathological material were recorded. Pathological staging was based 
on the tumour/nodes/metastases (TNM) system. 
The results were subject to statistical analysis using the R software version 3.5.4 (http://cran.r-
project.org). The U-Mann-Whitney test was used to compare two variables of non-parametric 
distribution, while the Kruskal-Wallis test and Dunn’s multiple comparison test were both 
used to assess the significance of differences between three or more groups. The Wilcoxon 
signed-rank test was used to compare related samples and repeated measurements. Finally, the 
correlation between qualitative variables was assessed with Fisher’s exact test. Statistical 
significance was set at 0.05 (p < 0.05). 
 
Results 
Of 103 screened patients, 89 (69 women and 20 men) aged 23–80 years (mean 46.6; median 
42) met the study’s criteria. Their serum PTH concentration ranged from 20 to 74 pg/mL, 
mean 43.2 pg/mL, median 42 pg/mL. The serum PTH showed a significant, positive 
correlation with the age of the patients (p = 0.0034, Pearson’s r = 0.3) and was negatively 
correlated with serum calcium (p = 0.04, Spearman R = –0.22). A negative correlation 
between PTH and 25-hydroxy vitamin D3 did not reach statistical significance (p = 0.164, 
Spearman’s R = –0.15). In addition, no significant difference between serum PTH for 25-
hydroxy vitamin D3 higher or lower than 20 ng/mL (p = 0.11) was found.  
Significant decreases in serum calcium, magnesium, and PTH concentrations were observed 
on POD1 in the entire patient group (p < 0.0001). Serum calcium and magnesium were 
positively correlated with PTH (p < 0.0001, Spearman’s R = 0.5; p = 0.006, Spearman’s R = 
0.4, respectively), and serum calcium was positively correlated with magnesium (p = 0.005, 
Spearman’s R = 0.4). With therapy initiated on POD1 in cases of hypocalcaemia, a gradual 
increase in serum calcium was noted over the two subsequent days, but serum magnesium 
continued to decrease. No difference in POD1 serum calcium between patients with normal 
serum 25-hydroxy-vitamin D3 and vitamin D3 deficiency was observed (p = 0.8).  
On POD1, the serum PTH concentration dropped below the normal range (POD1 PTH < 12 
pg/mL) in 29 patients, whereas it was undetectable (POD1 PTH < 6 pg/mL) in 19 patients. 
Biochemical hypocalcaemia in the early postoperative period, which occurred in 43 (48.3%) 
patients, was related to the absolute POD1 PTH concentration and the percentage decrease in 
serum PTH (p < 0.0001). The number of parathyroids that were found in the pathologic 
specimen, the tumour burden (pT1–2 vs. pT3–4), and age did not differ significantly between 
the patients with biochemical hypocalcaemia and those with a higher serum calcium (p = 
0.085, p = 0.43, p = 0.37, respectively). 
One year after surgery, 12 (13.6%) patients required treatment for hypocalcaemia and were 
diagnosed with permanent HypoPT. At one year after the surgery, their median serum calcium 
concentration while on treatment was 2.08 mmol/l (1.99–2.2 mmol/L). Daily doses of 
alphacalcidol ranged from 0.25 to 2 mcg, and calcium carbonate ranged from 1 to 3 g. The 
basal characteristics of patients with permanent hypocalcaemia are presented in Table 1.  
We found that PTH was undetectable on POD1 in all patients with permanent HypoPT. Seven 
other patients with undetectable POD1 PTH as well as all the patients with detectable POD1 
PTH did not require treatment for hypocalcaemia one year postoperatively.  
The relative risk (RR) of permanent HypoPT in cases of POD1 PTH of < 6 pg/mL was 88.75 
[95% confidence interval (CI): 5.49–1434.67; p = 0.0016]. The 95% CI range was wide 
because there were no cases of permanent HypoPT among patients with a POD1 PTH ≥ 6 
pg/mL, and the group with undetectable POD1 PTH was small.  
The Kruskal-Wallis test was used to compare clinical, surgical, and pre- and postoperative 
biochemical parameters in three groups of patients: those with permanent HypoPT, patients 
with an undetectable POD1 PTH concentration who recovered from hypocalcaemia, and 
patients with a POD1 PTH concentration of ≥ 6 pg/mL. The results are shown in Table 2. 
All of the patients with an undetectable POD1 PTH concentration had serum calcium 
concentration on POD1 that was significantly lower than in patients with a higher POD1 PTH 
concentration (median: 1.82 vs. 1.96, vs. 2.07 mmol/L; p < 0.001). The difference in serum 
POD1 calcium concentration between the patients who later developed permanent HypoPT 
and those who regained normocalcaemia despite an undetectable POD1 PTH concentration 
did not reach statistical significance, which may have been due to the small size of both 
subgroups (Fig. 1).  
On POD1, the median serum magnesium concentration was the lowest in patients who 
developed permanent HypoPT and the highest in patients with detectable POD1 PTH, but its 
absolute concentration, or the incidence of hypomagnesaemia, would not allow the prediction 
of permanent hypocalcaemia.  
One month postoperatively, serum calcium concentrations were lower in patients who 
developed permanent HypoPT than in all the patients who did not. However, the difference 
once again did not reach the level of statistical significance (median: 2.18 vs. 2.36 vs. 2.36 
mmol/L, p = 0.167). The patient groups were too small to draw conclusions regarding the 
threshold of serum calcium concentration that would be predictive of permanent 
hypocalcaemia. 
Upon pathological examination, a single parathyroid gland had been found in the material 
from four patients who developed permanent HypoPT, while none was found in the eight 
other specimens. Autotransplantation of a single parathyroid gland into the muscle had been 
performed on two patients with undetectable POD1 PTH, and permanent HypoPT developed 
in one of them. Thus, the number of parathyroid glands that were either removed or 
transplanted did not affect the long-lasting parathyroid dysfunction in the studied group of 
patients. 
One year postoperatively, in patients with persistent hypocalcaemia the serum PTH 
concentration was significantly lower than it had been before the operation (p = 0.003); 
however, it was subnormal in two patients only and normal the other 10 patients (Fig. 2). In 
the patients who recovered from hypocalcaemia despite an undetectable POD1 PTH 
concentration, the difference between the serum PTH concentration before and one year after 
the operation did not reach the level of significance (Tab. 3).  
One year after the operation, the serum PTH concentration in patients with permanent 
HypoPT was significantly lower than it was in all patients who did not require treatment for 
lasting hypocalcaemia (p < 0.001) and was lower than it was in patients with a POD1 PTH of 
< 6 pg/mL who regained normocalcaemia (Tab. 4, Fig. 3). 
 
Discussion 
The reported prevalence of early postoperative hypocalcaemia ranged from 7.6 to 83%, while 
permanent HypoPT may complicate 0.5 to 14% of total thyroidectomies [8–10, 12–14]. Large 
differences in the rates of early and permanent hypocalcaemia resulted from a lack of 
uniformly applied criteria for hypocalcaemia and HypoPT as well as from the varying extent 
of the operative procedures [8, 10, 15, 16]. Many authors have recently defined early 
postoperative hypocalcaemia as a total serum calcium concentration below 2 mmol/l or an 
ionised serum calcium below 1.0–1.05 mmol/L, although these values are lower than the 
reference ranges [9, 10, 16–19]. The choice of this threshold of postoperative hypocalcaemia 
was justified by blood dilution caused by a rise in the secretion of antidiuretic hormone as 
well as fluid therapy in the early postoperative period and by the fact that a higher serum 
calcium concentration is rarely accompanied by serious symptoms. The ESE has defined 
hypocalcaemia as an ionised or albumin-adjusted serum calcium concentration below the 
normal laboratory range [7].  
In the past, a dilemma regarding whether hypocalcaemia or abnormally low serum PTH 
should be considered a diagnostic feature of postoperative HypoPT was often solved in favour 
of serum PTH. In 2011, Promberger et al. described a group of eight patients with 
symptomatic hypocalcaemia and a normal serum PTH concentration at both 6 and 12 months 
after thyroidectomy [20]. The authors suggested a diagnosis of permanent relative HypoPT, 
noting that the patients’ serum PTH concentrations were significantly lower than they had 
been prior to their operations. This was also the case in our study. The serum PTH 
concentration did not reach the normal range in two of 12 patients with hypocalcaemia at one 
year postoperatively. In 10 other patients, although apparently normal, their serum PTH 
concentrations were insufficient to maintain normocalcaemia, and they were significantly 
lower than they had been prior to their operations. Hungry bone syndrome, 
hypercalcitoninaemia, hypomagnesemia, and/or vitamin D deficiency were not found in our 
patients. 
Lorente-Poch et al. classified permanent HypoPT into three categories: (1) aparathyroidism 
with undetectable PTH, (2) HypoPT with a serum PTH concentration below the normal range, 
and (3) relative parathyroid insufficiency, corresponding to a serum PTH concentration that is 
in the normal range but is insufficient for serum calcium normalisation [10]. Raffaelli et al. 
later extended this classification in cases of early postsurgical hypocalcaemia [21]. 
Recognition of patients with hypocalcaemia and an apparently normal PTH concentration as 
hypoparathyroid will increase the reported prevalence of postoperative HypoPT. 
We found that an undetectable serum PTH concentration on POD1 is an important risk factor 
of permanent HypoPT. No patient with a measurable POD1 PTH concentration required 
treatment for hypocalcaemia one year postoperatively. Our observation was in line with 
previous findings of other authors. For example, in eight patients described by Promberger et 
al. the serum PTH concentration dropped to 1 ± 0.8 pg/mL three hours postoperatively [20]. 
In a study on the factors related to the development of permanent HypoPT after total 
thyroidectomy in patients with Graves’ disease, Hammerstad et al. reported permanent 
hypoparathyroidism in four of 11 patients with an undetectable serum PTH concentration 6–
48 hours postoperatively and no cases of permanent hypocalcaemia in patients with a 
measurable serum PTH concentration [22]. In addition, Canu et al., in a retrospective study on 
permanent HypoPT, which they defined as a subnormal serum PTH concentration for more 
than 12 months after thyroidectomy, found that it occurred only in patients with an 
undetectable serum PTH concentration on POD1 [23]. 
Ten of 12 of our patients with permanent HypoPT suffered from relative parathyroid 
insufficiency, according to the classification proposed by Lorente-Poch et al. However, their 
serum PTH concentrations were significantly lower than they had been before the operation, 
and there were no perceivable reasons for an increased calcium requirement, meaning that 
parathyroid insufficiency in those patients should be considered absolute rather than relative. 
Therefore, we propose the term “functional” instead of “relative” for parathyroid 
insufficiency that presents as hypocalcaemia with a normal serum PTH concentration.  
In patients who were operated on for Graves’ disease, Hammerstad et al. observed that 
permanent HypoPT was associated with a significantly lower preoperative serum calcium 
concentration than for transient hypocalcaemia [22]. We did not confirm this observation in 
patients with papillary thyroid carcinoma, but hyperthyroidism was an exclusion criterion in 
our study. 
Genser et al. reported that in patients with permanent HypoPT the serum calcium 
concentration on POD1 was significantly lower than it was in patients who did not require 
permanent treatment for hypocalcaemia [24]. Notably, the serum PTH was not measured in 
that study. In our study the POD1 serum calcium concentration in patients with permanent 
HypoPT was significantly lower than it was in patients with measurable POD1 PTH. It was 
also lower than in patients with undetectable POD1 PTH, who later recovered from 
hypocalcaemia, but the difference did not reach statistical significance.  
Garrahy et al. found that hypomagnesaemia on POD1 was predictive of permanent 
hypocalcaemia in patients after total thyroidectomy [25]. Hammerstad et al. found a 
significant reduction in serum magnesium on POD2 in patients with permanent HypoPT 
compared to those with transient hypocalcaemia [22]. In the early postoperative period, a 
decrease in serum magnesium is secondary to that of serum PTH. In our study, both the serum 
magnesium concentration and the incidence of hypomagnesaemia on POD1 or serum 
magnesium concentration on POD2 did not allow the identification of patients at particular 
risk of permanent HypoPT among patients with undetectable POD1 PTH.  
Stiges-Serra et al. found that a higher serum calcium concentration one month postoperatively 
was the best biochemical predictor of recovery form protracted HypoPT [9]. In our study all 
patients with undetectable POD1 PTH required treatment for hypocalcaemia one month 
postoperatively, which corresponded to the definition of protracted HypoPT. In patients who 
later recovered from HypoPT, the serum calcium concentration was higher than it was in 
those who developed permanent HypoPT and equal to that of patients with detectable POD1 
PTH; however, the difference was less pronounced than that reported by Stiges-Serra et al., 
and it did not reach the threshold of significance.  
The hypothesis was formulated that a higher serum calcium concentration one month 
postoperatively promotes regeneration of the parathyroid glands. Should it be accurate, the 
mitigation of permanent HypoPT would not lie solely in the hands of surgeons. However all 
patients in our study were treated according to the same principle of keeping the serum 
calcium concentration at the lower edge of the normal range; therefore, we cannot exclude 
that the observation regarding better chances of recovery from HypoPT in patients with a 
higher serum calcium concentration may reflect a better regenerative potential of the 
parathyroid glands that underwent a reversible ischaemia of short duration.  
The number of parathyroid glands that are identified intraoperatively and left in situ is 
considered paramount to preventing postoperative hypoparathyroidism [26, 27]. Two intact 
parathyroid glands should suffice to prevent permanent hypoparathyroidism [26]. 
Intraoperative autotransplantation of the parathyroid glands into sternocleidomastoid muscle 
is advocated in cases of their removal or irreversible ischaemia; however, the role of 
autotransplantation in the prevention of permanent HypoPT has recently been questioned [8, 
9, 27]. A few authors have observed permanent hypocalcaemia in patients with two or more 
parathyroid glands left in situ [20, 22]. In addition, it has been proven that, in cases of 
permanent HypoPT, all parathyroid glands suffer irreversible vascular or thermal damage 
without the surgeon knowing about it [12, 20, 28]. The surgeon’s ability to assess the risk for 
the parathyroids may have a substantial impact on the complication rates [29]. Advances in 
the parathyroid glands’ intraoperative visualisation as well as the modification of guidelines 
for thyroid cancer management may help diminish the rate of this serious complication [12, 
30].  
We have addressed an important medical issue that is currently underrepresented in the 
medical literature. The organisation of our department, with specialists in surgery, 
endocrinology, and nuclear medicine working together, allows for comprehensive medical 
care. The prospective nature of this study and the selection of a homogenous group of patients 
allowed us to avoid bias, but it resulted in a small number of analysed subgroups. While this 
study was not innovative in its approach, the results have a solid foundation for interventional 
and focused studies on postoperative HypoPT.   
 
Conclusions 
An undetectable serum PTH concentration on POD1 constituted an important risk factor of 
permanent HypoPT, while a detectable PTH concentration has always been associated with 
full recovery of parathyroid glands function. In patients with permanent HypoPT the serum 
calcium concentrations on POD1 and one month postoperatively were lower than in patients 
who regained normocalcaemia; however, the differences did not reach statistical significance, 
which might have been related to the small sizes of the subgroups of patients. Further clinical 
experience tells us that patients who recovered from HypoPT despite an undetectable POD1 
PTH concentration should be monitored for hypocalcaemia in situations of increased calcium 
demand (i.e. related to pregnancy, breastfeeding, or medication) because they may require 
reimplantation of the treatment.  
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Figure 1. Serum calcium concentration on postoperative day 1 (POD1) in patients with 
permanent hypoparathyroidism (HypoPT), in patients with transient HypoPT despite an 
undetectable postoperative day 1 (POD1) parathormone (PTH) concentration, and in patients 
with a measurable PTH serum concentration on POD1. a–b: differences of statistical 
significance in post-hoc Dunn’s test (a: p < 0.001, b: p = 0.015) 
 
  
Figure 2. Serum parathormone (PTH) concentration in patients with permanent 
hypoparathyroidism (HypoPT): preoperatively and at one year postoperatively (p = 0.003)  
 
  
Figure 3. Serum parathormone (PTH) concentration at one year postoperatively: in patients 
who developed permanent hypocalcaemia, in patients with transient hypoparathyroidism 
(HypoPT) despite an undetectable postoperative day 1 (POD1) parathormone (PTH) 
concentration and patients with a measurable POD1 PTH concentration (a: p < 0.001)  
 
  
Table 1. Basal descriptive statistics for patients with permanent hypoparathyroidism 
(HypoPT) 
Permanent 
HypoPT  
n Mean SD Median Q1 Q3 Min. Max. 
Age, years 12 46.08 13.99 44.00 39.50 53.50 23.00 68.00 
25 (OH) vitamin 
D3 preop 12 21.57 11.96 20.62 14.34 23.55 8.06 51.48 
PTH preop 12 44.67 17.52 39.00 34.50 55.25 20.00 73.00 
Ca preop 12 2.35 0.10 2.36 2.29 2.40 2.21 2.56 
Ca POD1 12 1.84 0.16 1.82 1.78 1.94 1.56 2.11 
Ca 1 month 11 2.28 0.23 2.18 2.12 2.35 2.01 2.71 
Mg POD1 12 0.75 0.09 0.72 0.69 0.77 0.65 0.93 
Mg POD2 9 0.68 0.06 0.70 0.67 0.71 0.57 0.77 
Permanent 
HypoPT  
n Mean SD Median Q1 Q3 Min. Max. 
Lymph nodes 
dissected (n) 11 6.09 6.41 4.00 2.00 6.00 1.00 22.00 
Parathyroids 
autografted (n) 12 0.08 0.29 0.00 0.00 0.00 0.00 1.00 
Parathyroids 
removed (n) 12 0.33 0.49 0.00 0.00 1.00 0.00 1.00 
Reference ranges: Ca — serum total calcium 2.2–2.65 mmol/L; Mg — serum magnesium 0.77–1.06 mmol/L; 
25(OH)vitamin D3 > 20 ng/mL; PTH — parathormone 12–88 pg/mL; POD — postoperative day; SD — 
standard deviation 
 
Table 2. Comparison of selected variables between patients with permanent 
hypoparathyroidism (HypoPT), patients with transient HypoPT despite an undetectable 
postoperative day 1 (POD1) parathormone (PTH), and patients with a measurable PTH 
concentration on POD1 
Variable 
Undetectable  
POD1 PTH  
Measurable 
POD1 PTH   
p 
Permanent  
HypoPT (n = 12) 
Transient 
HypoPT (n = 7) 
Transient 
HypoPT or 
normocalcaemia  
(n = 70) 
Age 44.00  
(39.50; 53.50) 
33.00  
(31.50; 47.00) 
42.00  
(33.00; 64.00) 
0.476 
Sex     
Female 8 (66.7%) 6 (85.7%) 55 (78.6%) 0.641 
Male 4 (33.3%) 1 (14.3%) 15 (21.4%) 
25(OH) vitamin 
D3 preop. 
20.62  
(14.34; 23.55) 
12.01  
(10.81; 29.91) 
18.28  
(12.70; 24.35) 
0.875 
PTH preop. 39.00  
(34.50; 55.25) 
33.00  
(26.50; 39.50) 
43.00  
(31.00; 53.00) 
0.301 
Ca preop. 2.36 (2.29; 2.40) 2.46 (2.35; 2.48) 2.37 (2.29; 2.44) 0.446 
Ca POD1 1.82 (1.78; 1.94)a 1.96 (1.84; 1.97)b 2.07 (1.96; 2.15)ab < 
0.001* 
Variable 
Undetectable  
POD1 PTH  
Measurable 
POD1 PTH   
p 
Permanent  
HypoPT (n = 12) 
Transient 
HypoPT (n = 7) 
Transient 
HypoPT or 
normocalcaemia  
(n = 70) 
Ca 1 month 2.18 (2.12; 2.35) 2.36 (2.16; 2.46) 2.36 (2.28; 2.45) 0.167 
Mg POD1 0.72 (0.69; 0.77) 0.73 (0.72; 0.78) 0.78 (0.72; 0.82) 0.186 
Hypo Mg POD1 8 (66.7%) 5 (71.4%) 32 (46.4%) 0.248 
Mg POD2 0.70 (0.67; 0.71) 0.74 (0.63; 0.78) 0.73 (0.68; 0.81) 0.250 
Parathyroids 
removed (n) 
0.00 (0.00; 1.00) 0.00 (0.00; 0.50) 0.00 (0.00; 1.00) 0.974 
Parathyroids 
autografted (n) 
0.00 (0.00; 0.00) 
 
0.00 (0.00; 0.00) 
 
0.00 (0.00; 0.00) 
 
0.674 
Lymph nodes 
dissected (n) 
4.00 (2.00; 6.00) 2.00 (0.00; 3.00) 3.00 (1.00; 5.75) 0.180 
Variables are given in median (Q1; Q3) or as (% of the group). Kruskal-Wallis test and post-hoc Dunn’s test 
or exact Fisher test. a–bdifferences statistically significant in post-hoc Dunn’s test (ap < 0.001; bp = 0.015). *p 
< 0.05 
 
Table 3. Comparison between serum parathormone (PTH) concentration preoperatively and 
at 1 year postoperatively in patients with permanent hypoparathyroidism (HypoPT), patients 
with transient HypoPT despite an undetectable postoperative day 1 (POD1) PTH, and patients 
with a measurable PTH concentration on POD1 
Serum PTH 
Undetectable POD1 PTH 
Measurable POD1 
PTH 
Permanent  
HypoPT (n = 12) 
Transient  
HypoPT (n = 6) 
Transient HypoPT 
or normocalcaemia 
(n = 67) 
Preoperatively 39.00 (34.50; 55.25) 33.00 (26.50; 39.50) 43.00 (31.00; 53.00) 
Postoperatively  17.02 (13.34; 25.25) 32.00 (25.75; 40.50) 39.75 (29.75; 50.25) 
MD (95% CI) –21.98 (–37.38; –
13.00) 
–1.00 (–15.00; 7.00) –3.25 (–6.00; 1.00) 
p 0.003* 0.438 0.141 
Serum PTH 
Undetectable POD1 PTH 
Measurable POD1 
PTH 
Permanent  
HypoPT (n = 12) 
Transient  
HypoPT (n = 6) 
Transient HypoPT 
or normocalcaemia 
(n = 67) 
Data are given in median (Q1; Q3). Wilcoxon test (paired samples). MD — median difference and its 95% 
confidence interval (CI), *p < 0.05 
 
 
Table 4. Comparison of serum parathormone (PTH) concentration at 1 year postoperatively 
between patients with permanent hypoparathyroidism (HypoPT), transient HypoPT despite an 
undetectable postoperative day 1 (POD1) PTH, and patients with a measurable POD1 PTH 
concentration 
Variable 
Undetectable POD1 PTH 
Measurable POD1 
PTH 
p 
Permanent  
HypoPT (n = 12) 
Transient 
HypoPT (n = 6) 
Transient HypoPT or 
normocalcaemia (n = 
68) 
Serum PTH  
one year 
postoperatively 
17.02  
(13.34; 25.25)a 
32.00  
(25.75; 40.50) 
39.75  
(29.75; 50.25)a 
< 
0.001* 
Data are given in median (Q1; Q3). Kruskal-Wallis test with Dunn’s post-hoc test. a: difference statistically 
significant in post-hoc Dunn’s test (ap < 0.001), *p < 0.05 
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Czynniki ryzyka trwałej niedoczynności przytarczyc po całkowitym wycięciu gruczołu tarczowego i 
limfadenektomii szyjnej przedziału środkowego z powodu raka brodawkowatego tarczycy – 
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Streszczenie 
Wstęp:  Wycięcie lub uszkodzenie przytarczyc podczas zabiegów operacyjnych na przednim 
przedziale szyi odpowiada za ponad 80% przypadków przewlekłej niedoczynności przytarczyc. Celem 
pracy było określenie czynników związanych z trwałą niedoczynnością przytarczyc 
(hypoparathyroidism, HypoPT) po całkowitym wycięciu tarczycy i limfadenektomii szyjnej przedziału 
środkowego z powodu raka tarczycy. 
Materiał and metoda:  Kryteria udziału w badaniu o charakterze prospektywnej obserwacji spełniło 
89 z 103 wstępnie zakwalifikowanych chorych. Analizie statystycznej poddano czynniki 
demograficzne, chirurgiczne oraz biochemiczne parametry gospodarki mineralnej kontrolowane 
przed operacją i przez okres roku po zabiegu operacyjnym. Zgodnie z współczesnymi zaleceniami, za 
rozstrzygającą o rozpoznaniu pooperacyjnej HypoPT przyjęto hipokalcemię, a nie nieprawidłowo 
niskie stężenie parathormonu (PTH) w surowicy. 
Wyniki: W pierwszej dobie pooperacyjnej stężenie PTH w surowicy (POD1 PTH) obniżyło się poniżej 
zakresu normy (<12 pg/ml) u 29 chorych; u 19 chorych było niewykrywalne (<6 pg/ml). Rok po 
zabiegu operacyjnym leczenia z powodu hipokalcemii wymagało 12 chorych z niewykrywanym POD1 
PTH. Wszyscy pozostali pacjenci odzyskali czynność przytarczyc wystarczającą do utrzymania 
normokalcemii. Ryzyko względne trwałej HypoPT związanej z niewykrywalnym POD1 PTH wyniosło 
88,75. W POD1 u chorych z niewykrywalnym PTH stężenie wapnia w surowicy było istotnie niższe niż 
u chorych z oznaczalnym stężeniem PTH (p< 0,001). W podgrupie chorych z niewykrywalnym PTH, u 
chorych, u których po roku stwierdzono trwałą HypoPT stężenie wapnia było niższe niż u chorych z 
przemijającą HypoPT, jednak różnica ta nie osiągała istotności statystycznej (mediany: 1,82 mmol/l vs 
1,96 mmol/l). U chorych z trwałą niedoczynnością przytarczyc w miesiąc po operacji stężenie wapnia 
w surowicy było niższe niż u pozostałych chorych (p=0,167).  
Rok po zabiegu operacyjnym u 10 z 12 chorych z trwałą HypoPTH stężenie PTH mieściło się w zakresie 
normy, było jednak istotnie niższe od stwierdzanego przed operacją i niż u chorych z normokalcemią. 
Liczba wyciętych lub przeszczepionych przytarczyc nie miała wpływu na rozwój trwałej 
niedoczynności przytarczyc.  
Wnioski: Niewykrywalne POD1 PTH jest istotnym czynnikiem ryzyka trwałej niedoczynności 
przytarczyc, której główną przyczynę stanowiło w naszej pracy nieodwracalne uszkodzenie gruczołów 
przytarczycowych pozostawionych in situ.  
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